51.29
-0.48 (-0.93%)
| Previous Close | 51.77 |
| Open | 51.40 |
| Volume | 476,117 |
| Avg. Volume (3M) | 743,120 |
| Market Cap | 4,028,324,864 |
| Price / Sales | 650.22 |
| Price / Book | 3.22 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Diluted EPS (TTM) | -3.06 |
| Total Debt/Equity (MRQ) | 0.06% |
| Current Ratio (MRQ) | 8.06 |
| Operating Cash Flow (TTM) | -169.86 M |
| Levered Free Cash Flow (TTM) | -68.57 M |
| Return on Assets (TTM) | -25.34% |
| Return on Equity (TTM) | -65.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Spyre Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -3.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.40 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.71% |
| % Held by Institutions | 106.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fairmount Funds Management Llc | 31 Dec 2025 | 4,018,101 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (BTIG, 36.48%) | Buy |
| Median | 60.00 (16.98%) | |
| Low | 50.00 (Wells Fargo, -2.52%) | Buy |
| Average | 60.00 (16.98%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 43.21 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 20 Feb 2026 | 70.00 (36.48%) | Buy | 43.21 |
| 16 Jan 2026 | 70.00 (36.48%) | Buy | 33.24 | |
| Wells Fargo | 20 Feb 2026 | 50.00 (-2.52%) | Buy | 43.21 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BURROWS SCOTT L | - | 48.90 | -7,500 | -366,750 |
| SLOAN SHELDON | - | 48.90 | -7,958 | -389,146 |
| TURTLE CAMERON | - | 48.90 | -15,000 | -733,500 |
| Aggregate Net Quantity | -30,458 | |||
| Aggregate Net Value ($) | -1,489,396 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 48.90 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BURROWS SCOTT L | Officer | 01 Apr 2026 | Automatic sell (-) | 7,500 | 48.90 | 366,750 |
| BURROWS SCOTT L | Officer | 01 Apr 2026 | Option execute | 7,500 | - | - |
| SLOAN SHELDON | Officer | 01 Apr 2026 | Automatic sell (-) | 7,958 | 48.90 | 389,146 |
| SLOAN SHELDON | Officer | 01 Apr 2026 | Option execute | 7,958 | - | - |
| TURTLE CAMERON | Officer | 01 Apr 2026 | Automatic sell (-) | 15,000 | 48.90 | 733,500 |
| Date | Type | Details |
|---|---|---|
| 06 Feb 2026 | Announcement | Spyre Therapeutics Announces Grants of Inducement Awards |
| 23 Jan 2026 | Announcement | Spyre Therapeutics Announces Grants of Inducement Awards |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |